Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 9

PMID 35806381

Authors

Anica Dricu

Affiliations

Soon will be listed here.

Abstract

Cancer is a common name for several distinct diseases caused by uncontrolled cell growth and proliferation [...].

Citing Articles

Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors.

Aakriti J, Vithalkar M, Maity S, Baby K, Nagareddy P, Nayak Y Mol Biol Rep. 2025; 52(1):248.

PMID: 39976799 PMC: 11842479. DOI: 10.1007/s11033-025-10296-7.

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors.

Lutimba S, Saleem B, Aleem E, Mansour M J Xenobiot. 2024; 14(4):1962-1987.

PMID: 39728413 PMC: 11676455. DOI: 10.3390/jox14040105.

TRIM28 recruits E2F1 to regulate CBX8-mediated cell proliferation and tumor metastasis of ovarian cancer.

Zhang F, Zhu T, Wu C, Shen D, Liu L, Chen X Hum Cell. 2023; 36(6):2113-2128.

PMID: 37709991 DOI: 10.1007/s13577-023-00983-7.

An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.

Rodriguez S, Kamel A, Ciubotaru G, Onose G, Sevastre A, Sfredel V Int J Mol Sci. 2023; 24(13).

PMID: 37446288 PMC: 10341823. DOI: 10.3390/ijms241311110.

References

Serban F, Artene S, Georgescu A, Purcaru S, Tache D, Alexandru O . Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker. Onco Targets Ther. 2016; 8:3767-74. PMC: 4689259. DOI: 10.2147/OTT.S93843. View

Singh A, Harris R . Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal. 2005; 17(10):1183-93. DOI: 10.1016/j.cellsig.2005.03.026. View

Walsh J, KARNES W, Cuttitta F, Walker A . Autocrine growth factors and solid tumor malignancy. West J Med. 1991; 155(2):152-63. PMC: 1002946. View

Isozaki K, Hirota S . Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. Curr Genomics. 2008; 7(8):469-75. PMC: 2269002. DOI: 10.2174/138920206779315755. View

Dhillon A, Hagan S, Rath O, Kolch W . MAP kinase signalling pathways in cancer. Oncogene. 2007; 26(22):3279-90. DOI: 10.1038/sj.onc.1210421. View

Stern D . Keeping Tumors Out of the MAPK Fitness Zone. Cancer Discov. 2018; 8(1):20-23. DOI: 10.1158/2159-8290.CD-17-1243. View

Kentsis A, Reed C, Rice K, Sanda T, Rodig S, Tholouli E . Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012; 18(7):1118-22. PMC: 3438345. DOI: 10.1038/nm.2819. View

Hechtman J, Polydorides A . HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012; 136(6):691-7. DOI: 10.5858/arpa.2011-0168-RS. View

Stransky N, Cerami E, Schalm S, Kim J, Lengauer C . The landscape of kinase fusions in cancer. Nat Commun. 2014; 5:4846. PMC: 4175590. DOI: 10.1038/ncomms5846. View

10.

Dricu A, Kanter L, Wang M, Nilsson G, Hjertman M, Wejde J . Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Glycobiology. 1999; 9(6):571-9. DOI: 10.1093/glycob/9.6.571. View

11.

Neophytou C, Trougakos I, Erin N, Papageorgis P . Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers (Basel). 2021; 13(17). PMC: 8430856. DOI: 10.3390/cancers13174363. View

12.

Zhang J, Grubor V, Love C, Banerjee A, Richards K, Mieczkowski P . Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013; 110(4):1398-403. PMC: 3557051. DOI: 10.1073/pnas.1205299110. View

13.

Schlessinger J . Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 2004; 306(5701):1506-7. DOI: 10.1126/science.1105396. View

14.

Ambrogio C, Kohler J, Zhou Z, Wang H, Paranal R, Li J . KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018; 172(4):857-868.e15. DOI: 10.1016/j.cell.2017.12.020. View

15.

Mitelman F, Johansson B, Mertens F . The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007; 7(4):233-45. DOI: 10.1038/nrc2091. View

16.

Cattaneo F, Guerra G, Parisi M, De Marinis M, Tafuri D, Cinelli M . Cell-surface receptors transactivation mediated by g protein-coupled receptors. Int J Mol Sci. 2014; 15(11):19700-28. PMC: 4264134. DOI: 10.3390/ijms151119700. View

17.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

18.

Carapancea M, Alexandru O, Fetea A, Dragutescu L, Castro J, Georgescu A . Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol. 2008; 92(2):137-47. DOI: 10.1007/s11060-008-9753-8. View

19.

Wang Z, Zhang L, Xu W, Li J, Liu Y, Zeng X . The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in -Mutant NSCLC. J Inflamm Res. 2022; 15:649-667. PMC: 8818984. DOI: 10.2147/JIR.S341001. View

20.

Mongre R, Mishra C, Shukla A, Prakash A, Jung S, Ashraf-Uz-Zaman M . Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?. Int J Mol Sci. 2021; 22(21). PMC: 8584061. DOI: 10.3390/ijms222111659. View